Video

Dr. Jonasch on recent pivotal advances in renal cell carcinoma

Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses significant developments in renal cell carcinoma (RCC) over the last several years. He specifically focuses on the incorporation of immune checkpoint inhibitors into the frontline treatment of RCC and the emergence of HIF-2α inhibitors, such as belzutifan (Welireg).

Related Videos
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
 Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Human kidney cross section on scientific background | © Crystal light - stock.adobe.com
Jaleh Fallah, MD, answers a question during a Zoom video interview
Human kidney cross section on science background | Image Credit: © Rasi - stock.adobe.com
Human kidney cross section on science background | Image Credit: © Crystal light - stock.adobe.com
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.